Chronic nonspecific low back pain
Conditions
Interventions
Combined intervention group (rTMS+TENS):Repetitive transcranial magnetic stimulation (10Hz, 80% MT, left M1 area, 20min/session) + transcutaneous electrical nerve stimulation (100Hz, L3-L4 erector spi
rTMS monotherapy group (real rTMS + sham TENS):Repetitive transcranial magnetic stimulation (same parameters as above) + sham TENS (no current output, same instrument settings as real stimulation), 3
TENS monotherapy group (sham rTMS + real TENS):Sham rTMS (coil reversed, no effective magnetic field output, same sound and vibration as real stimulation) + transcutaneous electrical nerve stimulation
Sham stimulation control group (sham rTMS + sham TENS):Sham rTMS + sham TENS (no effective intervention output, same instrument settings as real stimulation), 3 times/week for 4 weeks
Sponsors
Beijing Sport University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Meet the diagnostic criteria for chronic nonspecific low back pain according to the Guidelines for the Diagnosis and Treatment of Chronic Nonspecific Low Back Pain, with low back pain lasting >=12 weeks; 2.Aged 18~65 years, regardless of gender; 3.Visual Analogue Scale (VAS) score for low back pain >=3 at enrollment; 4.Able to understand and sign the informed consent form, voluntarily participate in this study, and cooperate with the intervention and follow-up procedures.
Exclusion criteria
Exclusion criteria: 1.Patients with specific low back pain (e.g., lumbar fracture, infection, tumor, tuberculosis, disc herniation with nerve root compression, lumbar spondylolisthesis, etc.); 2.Patients with contraindications to rTMS or TENS treatment: such as intracranial metal implants, history of epilepsy, increased intracranial pressure, severe heart disease, pacemaker implantation, skin damage/infection at the treatment site, severe peripheral neuropathy, etc.; 3.Patients who received hormones, opioid analgesics, or antiepileptic drugs within the past 3 months, or participated in other low back pain-related clinical trials; 4.Pregnant or lactating women, or those planning to become pregnant during the study period; 5.Patients with cognitive impairment or mental illness (such as severe depression, schizophrenia) who cannot cooperate with the assessment; 6.Patients with severe systemic diseases affecting the implementation of the study, such as severe liver and kidney dysfunction, malignant tumors, severe cardiovascular and cerebrovascular diseases; 7.Patients with a history of alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Visual Analogue Scale (VAS) score for low back pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Oswestry Disability Index (ODI) score;Pressure Pain Threshold (PPT) of bilateral L3-L4 erector spinae;Cross-sectional Area (CSA) of multifidus muscle;Tensiomyography (TMG) parameters of erector spinae/multifidus muscle (Dm, Tr, Ts); | — |
Countries
China
Contacts
Public ContactZhao Haoran
Beijing Sport University
Outcome results
None listed